Skip to main content

Table 2 Descriptive statistics of bone mineral density lumbar spine and hip percentage change from baseline at 12 and 24 months

From: Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial

  

BMD lumbar spine percentage change from baseline

BMD hip percentage change from baseline

  

T ≤ -2, A+R

-2 < T < -1, A

-2 < T < -1, A+R

T ≥ -1, A

T ≤ -2, A+R

-2 < T < -1, A

-2 < T < -1, A+R

T ≥ -1, A

12 months

Median

6.3%

0.0%

-0.4%

-5.3%

-1.9%

-1.3%

0.0%

-2.4%

 

IQR

12.0%

12.0%

9.2%

8.2%

11.0%

11.0%

8.6%

6.7%

 

P value

< 0.001

0.70

0.68

< 0.001

0.30

0.22

0.76

< 0.001

24 months

Median

6.6%

-1.5%

5.7%

-2.5%

-1.9%

-3.9%

1.6%

-5.7%

 

IQR

17.0%

11.0%

14.0%

10.0%

19.0%

12.0%

15.0%

13.0%

 

P value

< 0.001

0.25

0.01

< 0.001

0.16

0.02

0.50

0.09

  1. A, anastrozole; BMD, bone mineral density; IQR, interquartile range; R, risedronate; T, T-score.